Skip to main content

Table 1 Baseline characteristics of women without cancer and women with local or systemic cancer

From: Responses to fertility treatment among patients with cancer: a retrospective cohort study

Characteristics at cycle start

No Cancer (nā€‰=ā€‰664)

Local Cancer (nā€‰=ā€‰105)

Systemic Cancer (nā€‰=ā€‰42)

Womanā€™s Age at Stimulation, years (meanā€‰Ā±ā€‰SD)

34.6ā€‰Ā±ā€‰4.2

33.6ā€‰Ā±ā€‰4.8

27.1ā€‰Ā±ā€‰6.4

Baseline Antral Follicle Count (meanā€‰Ā±ā€‰SD) (missing, nā€‰=ā€‰48)

9.4ā€‰Ā±ā€‰7.2

10.1ā€‰Ā±ā€‰7.4

7.3ā€‰Ā±ā€‰7.5

AMH, ng/mL (meanā€‰Ā±ā€‰SD)

3.4ā€‰Ā±ā€‰3.3

2.8ā€‰Ā±ā€‰2.7

2.0ā€‰Ā±ā€‰2.2

CycleĀ Day 2ā€“4 FSH, mIU/mL (meanā€‰Ā±ā€‰SD) (missing, nā€‰=ā€‰91)

7.2ā€‰Ā±ā€‰2.3

9.6ā€‰Ā±ā€‰19.8

9.1ā€‰Ā±ā€‰6.3

Womanā€™s BMI at Stimulation, kg/m2 (meanā€‰Ā±ā€‰SD)

25.7ā€‰Ā±ā€‰4.2

26.0ā€‰Ā±ā€‰6.3

24.9ā€‰Ā±ā€‰5.9

Womanā€™s Race (n [%])

ā€ƒCaucasian

466 (70.2%)

88 (86.2%)

36 (85.7%)

ā€ƒOther

198 (29.8%)

14 (13.7%)

6 (14.3%)

Current Smoker (n [%])

17 (2.6%)

6 (5.7%)

0 (0%)

Gravida (n [%])

186 (28.3%)

35(33.3%)

7 (16.7%)

Cycle Type (n [%])

ā€ƒGnRH antagonist

88 (13.3%)

103 (98.1%)

36 (85.7%)

ā€ƒDown-regulation

533 (80.3%)

1 (1.0%)

4 (9.5%)

ā€ƒGonadotropin only

3 (0.5%)

1 (1.0%)

2 (4.8%)

ā€ƒPoor-responder protocols

40 (6.0%)

0 (0%)

0 (0%)

Start of Stimulation (n [%])

ā€ƒConventional/Early Follicular

664 (100.0%)

84 (80.0%)

25 (59.5%)

ā€ƒRandom Start

0 (0%)

16 (14.3%)

17 (40.5%)

ā€ƒā€ƒLate Follicular

0 (0%)

3 (2.9%)

2 (4.8%)

ā€ƒā€ƒLuteal

0 (0%)

7 (6.7%)

5 (11.9%)

Total Motile Post-wash Sperm Count, 106 (meanā€‰Ā±ā€‰SD)

5.66ā€‰Ā±ā€‰16.88

28.9ā€‰Ā±ā€‰33.4

34.8ā€‰Ā±ā€‰41.5

ICSI (n [%])

547 (85.6%)

21 (21.7%)

4 (11.4%)